#USA #San Diego #VST BIO #VB-001 #William Sessa

VST BIO Corporation's Milestone in Stroke Therapeutics Development

Introduction
In a significant step for its development goals, VST BIO Corporation, a biotechnology firm pioneering treatments for stroke, has announced the successful completion of its Series A financing. This round was led by Coefficient Giving, a philanthropic fund that collaborates with donors to enhance impactful giving in crucial sectors like health and science. Since its foundation in 2020, Coefficient Giving has provided VST BIO with a robust $45 million in funding.

Advancement of VB-001
The capital raised from this Series A will facilitate the progress of VST BIO's main therapeutic program, VB-001, towards human clinical trials scheduled for 2026. This funding is not just a financial lifeline; it will also aid in expanding the company's operational framework and developing essential capabilities that will support ongoing and future research projects. The CEO and Chairman of VST BIO, Dr. Krisztina Zsebo, expressed satisfaction with the financing, highlighting that the encouraging preclinical outcomes from monoclonal antibody research indicate VB-001's potential as a vital treatment for individuals afflicted by acute ischemic stroke.

Board Appointment
As part of this financing initiative, VST BIO has introduced William Sessa to its Board of Directors as of March 3, 2026. With an extensive background, Bill has previously held influential roles, including Senior Vice President and Chief Scientific Officer of Internal Medicine at Pfizer until mid-2025. He oversaw pioneering programs linking metabolic disturbances to cardio-renal conditions and successfully transitioned numerous novel compounds into clinical settings. Additionally, he is recognized as the Alfred Gilman Emeritus Professor at Yale School of Medicine's Pharmacology Department.

Dr. Michael Simons, co-founder of VST BIO, emphasized the tremendous asset Sessa brings to the organization with his decades of experience in progressing vascular therapeutics from research into clinical trials, proving invaluable for the company's upcoming developmental phase.

A Transformative Approach to Stroke
Expressing enthusiasm about joining VST BIO, William Sessa remarked on the company's innovative trajectory in developing a first-in-class molecule that addresses vascular inflammation in stroke patients. He believes that the extensive preclinical data supporting VB-001 could redefine therapeutic strategies for stroke treatment. This innovative approach embodies the mission of VST BIO to deliver impactful solutions to patients enduring these life-altering conditions.

About VST BIO Corporation
VST BIO operates at the forefront of biotechnology, concentrating on preclinical research centered on vascular complications, particularly ischemic stroke. Their flagship candidate, VB-001, has shown promise across various disease contexts, including stroke and sepsis, and is poised to mitigate cytokine release syndromes in numerous clinical applications. VST BIO is based in San Diego, California, having established itself as a pioneering force in stroke therapy.

Conclusion
With the closure of the Series A financing and the strategic addition of William Sessa, VST BIO Corporation is set for significant advancements within the biopharmaceutical sector. The positive preclinical results pave the way forward, presenting hope for many stroke patients awaiting effective therapeutic innovations. For more information, visit VST BIO's official website.

Media and Investor Relations
For inquiries, please contact:
Rebecque Laba, COO
VST BIO Corporation
Phone: (858) 665-2009
Email: [email protected]